DJIA 16,408.54 -16.31 -0.10%
NASDAQ 4,095.52 0.00 0.00%
S&P 500 1,864.85 2.54 0.14%
market minute promo

company name or ticker
Company Photos
(Click to zoom)

FDA Clears AstraZeneca's Myalept - Analyst Blog

Acadia Pharmaceuticals: Here's What You Should Know About Its Surging Shares

Acadia's (ACAD) promising drug for Parkison's and Alzheimer's has investors cheering

Dividend Derby: Bristol-Myers Squibb Vs. AstraZeneca

Bristol-Myers and AstraZeneca offer nice dividend yields, but patent expiration may mean dividend investors are taking on risk.

After Cangrelor, The Medicines Company Gets Priority Review for New Drug

After its anti-clotting agent Cangrelor was rejected by an FDA committee, The Medicines Company sets its sights on getting approval for skin infection drug oritavancin.

AstraZeneca (AZN) Hits New Lifetime High

5 Pharmas Spending the Most to Develop Drugs: Merck, AstraZeneca, Roche, Bristol, and Lilly

Eli Lilly, Bristol-Myers Squibb, Roche, AstraZeneca, and Merck top the charts.

Watch For Today's Momo Momentum Stock: AstraZeneca (AZN)

3 Under-the-Radar Biotech Stocks You Need to Watch in 2014

Nektar Therapeutics, Omeros, and Spectrum Pharmaceuticals all face off with regulators in key decision dates for their developmental drugs later this year

Will Hospira's Lack of a Dividend Hold It Back in 2014?

Hospira (NYSE: HSP) currently pays no dividend. Could this mean that shares struggle to keep pace with the S&P 500 this year?

2 FDA Decisions You Need to Watch Next Week

An experimental rare disease drug and another experimental drug that's been rejected three previous times are this week's must-watch FDA events.
See More Articles...